Loyal, the San Francisco animal-health company founded by Celine Halioua, announced on September 16, 2026 that its drug candidate LOY-003 had completed the Reasonable Expectation of Effectiveness (RXE) section of its application for Expanded Conditional Approval (XCA) from the US Food and Drug Administration1. LOY-003 is a pill intended to extend the lifespan of large dogs1.
The review was done by the FDA's Center for Veterinary Medicine, which regulates drugs for animals. The acceptance covers one part of an application. It is not an approval, and LOY-003 cannot be sold or prescribed on the strength of it.
What happened
With LOY-003's acceptance, Loyal says all three drugs in its current pipeline have now completed the efficacy requirement for conditional approval, which the company describes as a first for any company1. The two earlier acceptances were for LOY-001, a large-dog drug whose RXE was announced in November 202389, and LOY-002, a pill for senior dogs whose RXE was accepted in February 20257.
In a blog post published the same day, Loyal described LOY-003 as a once-daily oral tablet for large and giant-breed dogs that is designed to lower growth hormone (GH) and insulin-like growth factor 1 (IGF-1)2. LOY-001 targets the same hormones but is a long-acting injection given by a veterinarian every three to six months9. LOY-003 is, in effect, the pill version of that idea12.
"Bringing a drug through the FDA regulatory process is rigorous and complex. The agency sets and upholds standards that dog owners and veterinarians can trust, which is why we chose to pursue this path." Celine Halioua, founder and CEO of Loyal1
What the FDA step means
Conditional approval is a route the FDA offers for some animal drugs that address an unmet need and would require long or complex studies to prove they work. According to Loyal's own explainer, expanded conditional approval rests on three technical packages3:
- Target Animal Safety (TAS): full safety data in the species the drug is meant for.
- Chemistry, Manufacturing and Controls (CMC): full data showing the drug can be made consistently.
- Reasonable Expectation of Effectiveness (RXE): evidence from shorter studies that the drug is likely to achieve its intended effect.
What conditional approval does not require is a completed pivotal, randomized, placebo-controlled trial showing that the drug actually extends lifespan3. A conditionally approved drug can be on the market for up to five years while the company finishes that study; if the study fails to show effectiveness, the drug is taken off the market38.
So the September acceptance means FDA reviewers judged the LOY-003 efficacy data sufficient for this one section. For LOY-003, the safety and manufacturing sections have not been reported as complete, and the September announcement did not mention them1.
The evidence so far
Loyal's announcement did not describe which studies were submitted for the LOY-003 efficacy section1. For the earlier LOY-001 acceptance, Loyal said the package included interventional studies in a canine aging model that the FDA had accepted, an observational study of about 450 dogs with no drug given, and quality-of-life and health assessments by owners and veterinarians9. Trade coverage at the time reported that the LOY-001 data showed the drug could reduce IGF-1 levels in dogs8.
The biological rationale is drawn from size differences between breeds. Loyal states that large dogs carry 2 to 30 times more IGF-1 than smaller breeds and notes that Great Danes average 6 to 8 years of life while Chihuahuas can live up to 202. The company also points to decades of research, starting with Cynthia Kenyon's 1993 finding that mutations in insulin/IGF-1 signaling genes doubled the lifespan of roundworms, as support for the idea that lowering GH and IGF-1 signaling can extend lifespan across species2. These are the company's framing of prior research, not results from LOY-003 itself.
| Drug | Target dogs | Form | Accepted FDA sections |
|---|---|---|---|
| LOY-001 | Large and giant breeds | Injection every 3 to 6 months | RXE (Nov 2023) |
| LOY-002 | Senior dogs, 10 years and older | Daily pill | RXE (Feb 2025), TAS (Jan 2026) |
| LOY-003 | Large and giant breeds | Daily pill | RXE (Sep 2026) |
What it does not show yet
No Loyal drug has yet been shown in a completed controlled trial to make dogs live longer. The company's pivotal lifespan study, called STAY, is testing LOY-002 rather than LOY-0031. It compares LOY-002 with a placebo in about 1,300 senior dogs and is fully enrolled7, across 70 veterinary clinics according to trade coverage6. Results on lifespan are not yet available.
LOY-002 is also the furthest along in the regulatory process. In January 2026 the FDA accepted its safety section, based on a controlled study at 1, 3 and 5 times the intended dose in which no clinically significant adverse events were reported, plus field data from more than 400 dogs in STAY followed for up to one year47. Veterinary Practice News described this as the first known safety acceptance for a lifespan extension drug in any species5. The manufacturing section is still outstanding, and dvm360 reported that Loyal expects that final section to be reviewed in 20274.
For LOY-003 specifically, three things remain unknown from public information: what the efficacy data showed in numbers, how long safety and manufacturing reviews will take, and whether a separate pivotal lifespan study will be needed for it after any conditional approval.
Who is behind it
Loyal describes itself as a clinical-stage animal health company and says it has raised more than $250 million to date1. All descriptions of the drugs, their mechanisms and their regulatory status in this article come from the company or from trade coverage based on company announcements; the FDA does not publish its reviews of individual technical sections, and no independent statement from the agency on LOY-003 was available. The company's quotes and its comparison of breeds should be read as advocacy for its own approach.
How it fits the field
Loyal's strategy is to target aging itself rather than a named disease of aging, and the company frames LOY-002 as on track to be the first drug approved for lifespan extension in any species1. With LOY-003, the company now has efficacy acceptances across its whole current pipeline1, and its lead drug has passed the safety review as well5. By the company's account, no other drug has gone this far toward an FDA label for lifespan extension15. Still, a conditional approval for any of these drugs, if it comes, would rest on an expectation of effectiveness rather than proven longer lives3.
What to watch next
- Whether the FDA accepts the manufacturing section for LOY-002, which would complete its three main sections; Loyal has pointed to 2027 for that review4.
- Any public data from the STAY study on lifespan, quality of life or safety.
- Whether Loyal reports safety or manufacturing submissions for LOY-001 or LOY-003.
- Independent, peer-reviewed publication of the efficacy data behind each RXE acceptance.
